PMID- 12776011
OWN - NLM
STAT- MEDLINE
DCOM- 20030619
LR  - 20071115
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 4 Suppl 2
DP  - 2003
TI  - Cardiac resynchronization therapy: a review of clinical trials and criteria for 
      identifying the appropriate patient.
PG  - S30-7
AB  - Numerous clinical trials have evaluated the safety and efficacy of cardiac 
      resynchronization therapy in patients with moderate or severe heart failure and 
      ventricular dyssynchrony. Initial studies were observational or mechanistic in 
      design and enrolled small numbers of patients. These investigations provided 
      proof of concept in support of resynchronization therapy by demonstrating acute 
      and chronic improvements in hemodynamics, echocardiographic measures of cardiac 
      performance, and functional status. Of these early studies, the InSync Trial 
      stands out as particularly important in suggesting the long-term clinical 
      benefits of cardiac resynchronization therapy in advanced heart failure. Later, a 
      series of randomized, controlled trials was initiated to definitively evaluate 
      the effects of cardiac resynchronization on patient status and clinical outcomes. 
      These landmark investigations included the MUSTIC, MIRACLE, MIRACLE ICD, and 
      CONTAK CD trials. These studies consistently demonstrated statistically 
      significant improvements in quality of life, New York Heart Association (NYHA) 
      functional class ranking, exercise tolerance, and left ventricular reverse 
      remodeling. Some studies suggested reductions in morbidity and mortality. This 
      latter observation was confirmed by a recent, large-scale morbidity and mortality 
      trial of cardiac resynchronization therapy in heart failure. Given these 
      findings, cardiac resynchronization therapy should be routinely considered in 
      eligible NYHA Class III and IV heart failure patients with ventricular 
      dyssynchrony.
FAU - Abraham, William T
AU  - Abraham WT
AD  - Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, 
      Ohio State University, Columbus, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - 0 (Anti-Arrhythmia Agents)
SB  - IM
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - Cardiac Pacing, Artificial
MH  - Heart Failure/*therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Ventricular Dysfunction, Left/*therapy
RF  - 30
EDAT- 2003/05/31 05:00
MHDA- 2003/06/20 05:00
CRDT- 2003/05/31 05:00
PHST- 2003/05/31 05:00 [pubmed]
PHST- 2003/06/20 05:00 [medline]
PHST- 2003/05/31 05:00 [entrez]
PST - ppublish
SO  - Rev Cardiovasc Med. 2003;4 Suppl 2:S30-7.